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HIV-1HXB2 5′LTR region, most of BIVR29 gag-pol segment and HIV-1HXB2 pol IN-3′LTR region were 
respectively amplified. A chimeric clone, designated as pHBIV3753, was constructed by cloning three 
fragments sequentially into pUC18. MT4 cells were transfected with pHBIV3753. The replication and 
expressions of the chimeric virus (HBIV3753) were monitored by RT activity and IFA. The results 
firstly demonstrated that it is possible to generate a new type of the BIV/HIV-1 chimeric virus con-
taining BIV gag-pol gene.
The development of safe, effective HIV vaccines is considered to be one of the most important ways 
to control the incidence of HIV infection [1]. Among the various types of vaccines developed, atten-
uated vaccines have the advantage that they mimic natural virus infection in the host. Although an 
HIV vaccine for humans has not yet been produced, SIV or SHIV vaccines attenuated by gene modi-
fication have protected monkeys from homologous and heterologous challenge viruses [2]. However, 
their safety for human use is questionable because they can cause fatal immune system disease [3].
Bovine immunodeficiency virus (BIV), a non-primate lentivirus, more closely resembles human and 
non-human primate immunodeficiency viruses in structure, immunology and genetics, and is unable 
to infect humans or human cells [4]. There is, therefore, the possibility of constructing a new chime-
ric virus to be used as an attenuated vaccine against HIV. In this work, we sought to construct a se-
ries of chimeric viruses of BIV and HIV-1 to generate a chimeric virus that can be used as a candidate 
for attenuated vaccine. We successfully generated a himeric virus/H(BIV) that contains the gag-pol 
gene from BIV.
The complementary DNA sequence data of BIVR29 and HIV-1HXB2 are from GenBank. The following 
gene segments were obtained by polymerase chain reaction (PCR), using pHXB2 or pBIV plasmids as 
templates. The first segment was the entire HIV-1 5′ long-term repeat (LTR) region (1 ~ 19 nt and 788 
~ 776 nt). The second segment contained most of the BIVR29gag-pol segment (701 ~ 727 nt and 4444 ~ 
4421 nt). The third was the HIV-1HXB2 pol IN -3′LTR region (4377 ~ 4411 nt and 9719 ~ 9696 nt). Two 
ends of three pairs of primers included different enzyme sites, respectively. PCR products were then 
digested by respective enzymes and ligated sequentially into predigested pUC18 vector (Figure 1a). 
The recombinant chimeric clone was designated as pHBIV3753. It was verified by Xba I, Bam HI, Hin 
dIII, Bgl I, and Pst I enzyme digestion.
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Fig. 1. Genetic structure and biological activity of HBIV3753. (a) Genome organization of the chimeric clone. The arrowheads 
indicate the positions of enzyme sites used to make the recombinant. White boxes represent long-term repeats (LTR) and 
open reading frames from pHXB2. Black boxes represent gag-pol, not including the IN region of pol, from primate bovine im-
munodeficiency virus (pBIV). (b) Kinetics of HBIV3753 replication in MT4 cells. Viral replication was monitored by reverse 
transcriptase (RT) activity of culture supernatants. (c) Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of 
BIV gag and HIV-1 tat reverse transcripts of HBIV3753. Lanes 2-4: RT-PCR amplification of BIV gag fragments; lanes 5-7: PCR 
amplification of BIV gag fragments used as control; using the cellular RNA as templates at 2, 4, 7 days post-transfection, re-
spectively (c1). Lanes 2-4: RT-PCR amplification of the full-length HIV-1 tat fragments, the cellular RNA from cells transfec-
ted with pHXB2 used as controls; lanes 5-7: RT-PCR amplification of HBIV3753; collected 5, 6, 7 days post-transfection, respec-
tively (c2). (d) BIV or HIV-1 antigen expressions in MT4 cells transfected with the chimeric clone. The smears were prepared 
at 48 hours post-transfection and analysed by indirect immunofluorescence assay with either mouse anti-BIV p26 monoclonal 
antibody (d1) or human anti-HIV-1 antibody (d2).
Equivalent quantities of pHBIV3753 or pHXB2 plasmid were introduced into MT4 cells by electro-op-
eration. The culture supernatant from transfected cells was collected from 1 to 7 days. To assess vi-
rus replication kinetics, the virion-associated reverse transcriptase (RT) activity was determined by 
a BrdUTP incorporation assay (Cavidi Tech AB, Sweden). The level of RT activity peaked at 5 days 
post-transfection (Figure 1b). BIV replicative capacity was lower than that of HIV-1. Although the 
promoters and regulatory protein of HIV-1 were used in HBIV3753, the gag-pol gene came from BIV. 
Therefore, HBIV3753 replicative ability was lower than that of HIVHXB2.
At 2, 4, and 7 days post-transfection, the cells were harvested and the total RNA of transfected cells 
was extracted. BIV gag gene transcript of HBIV3753 was amplified by RT-PCR (Figure 1c 1). For 5-7 
days post-transfection, the HIV-1 tat gene transcript of HBIV3753 was obtained by RT-PCR (Figure 1c 
2). Our results showed that despite the HIV-1 gag-pol region being replaced by BIV gag-pol, HBIV3753 
could form full-length and splicing transcripts.
ConstruCtion and CharaCterization of a ChimeriC Virus (BiV/hiV-1) Carrying the BoVine immunodefiCienCy Virus gag-pol gene
The antigenicity of HBIV3753 was analysed by indirect immunofluorescent assay (IFA). Forty-eight 
hours post-transfection, the cells exposed to mouse anti-BIV p26 monoclonal antibody showed a flu-
orescence signal only in the cytoplasm. The cells also reacted with HIV-1-positive serum, and a fluo-
rescence signal appeared both on the cell membrane and in the cytoplasm. These data indicate correct 
HBIV3753 gene expression and also show correct antigenicity for two kinds of viral proteins (Figure 1d).
This is the first demonstration to show the use of a BIV gene to replace the structural gene of HIV-1, 
and thereby create a new type of HBIV3753, which contains biological activity. The final goal of authors 
is to obtain a safe, effective, and attenuated chimeric virus. In our laboratory, a series of BIV/HIV-1 
chimeric clones are being constructed and analysed.
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